Masthead
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Editorial Board
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Table of Contents
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Advances in Chronic Kidney Disease as Syntopicon
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Jerry Yee (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Cardiovascular Calcifications Among Patients With Uremia: Answers to Hard Questions
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Sagar U. Nigwekar (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Mineral Bone Abnormalities and Vascular Calcifications
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Matthew Ray, Anna JovanovichVascular calcification (VC) is common in chronic kidney disease, increases in prevalence as patients progress to end-stage renal disease, and is significantly associated with mortality. VC is a complex and highly regulated process similar to bone formation whereby hydroxyapatite crystals deposit in the intimal or medial layer of arteries. Mineral bone abnormalities are common in chronic kidney disease; reduction in glomerular filtration rate and changes in vitamin D, parathyroid hormone, and f...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Mechanisms of Vascular Calcification in Kidney Disease
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Sinee Disthabanchong, Praopilad SrisuwarnThe increase in prevalence and severity of vascular calcification in chronic kidney disease is a result of complex interactions between changes in the vascular bed, mineral metabolites, and other uremic factors. Vascular calcification can occur in the intima and the media of arterial wall. Under permissive conditions, vascular smooth muscle cells (VSMCs) can transform to osteoblast-like phenotype. The membrane-bound vesicles released from transformed VSMCs and the apoptotic bodies...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

The Role of Nonenzymatic Post-translational Protein Modifications in Uremic Vascular Calcification
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Kenneth Lim, Sahir KalimConsiderable technological advances have enabled the identification and linkage of nonenzymatic post-translationally modified proteins to the pathogenesis of cardiovascular disease (CVD) in patients with kidney failure. Through processes such as the nonenzymatic carbamylation reaction as well as the formation of advanced glycation end products, we now know that protein modifications are invariably associated with the development of CVD beyond a mere epiphenomenon and this has become an important f...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

The Role of Vitamin K in Vascular Calcification
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Mario Cozzolino, Maria Fusaro, Paola Ciceri, Lorenzo Gasperoni, Giuseppe CiancioloVascular calcification (VC) is common in advanced chronic kidney disease (CKD), contributes to cardiovascular disease (CVD), and associates with increased mortality. Major risk factors for VC in CKD are increasing age, dialysis vintage, and positive net calcium-phosphate balance. To date, no specific therapy that prevents progression or facilitates regression of VC beyond careful attention to calcium and phosphate balance exists. Accumulati...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Diagnostic Tests for Vascular Calcification
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Edward R. Smith, Tim D. Hewitson, Stephen G. HoltVascular calcification (VC) is the heterogeneous endpoint of multiple vascular insults, which varies by arterial bed, the layer of the arterial wall affected, and is propagated by diverse cellular and biochemical mechanisms. A variety of in vivo and ex vivo techniques have been applied to the analysis of VC in preclinical studies, but clinical examination has principally relied on a number of noninvasive and invasive imaging modalities for detection and quantitat...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Valvular Calcification in Chronic Kidney Disease
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Vincent M. Brandenburg, Alexander Schuh, Rafael KramannAccelerated and premature cardiovascular calcification is a hallmark of patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD). The presence and the amount of cardiovascular calcification are among the driving forces of increased morbidity and mortality in renal patients. Cardiovascular calcification occurs at different sites, including the cardiac valves—a location that is of particular importance for both the patient and the treating phy...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Bone-Vascular Axis in Chronic Kidney Disease
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Pieter Evenepoel, Britt Opdebeeck, Karel David, Patrick C. D'HaesePatients with chronic kidney disease (CKD) are at increased risk of osteoporosis and vascular calcification. Bone demineralization and vascular mineralization go often hand in hand in CKD, similar to as in the general population. This contradictory association is independent of aging and is commonly referred to as the “calcification paradox” or the bone-vascular axis. Various common risk factors and mechanisms have been identified. Alternativel...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Calciphylaxis: Approach to Diagnosis and Management
Publication date: November 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 6Author(s): Harish Seethapathy, Lama NoureddineCalciphylaxis is a rare disorder of poor prognosis that can lead to intense, painful lesions involving the skin and subcutaneous tissue. Although mostly described in dialysis patients, it can affect patients with normal kidney function. The diagnosis of calciphylaxis is complicated by the absence of a gold standard marker of disease such as a clear histopathological finding. Late diagnosis and advanced lesions can significantly shorten life expectancy. Calciphylaxis wounds can have a ma...
Source: Advances in Chronic Kidney Disease - December 11, 2019 Category: Urology & Nephrology Source Type: research

Masthead
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Editorial Board
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Table of Contents
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Lupus Nephritis: Breaking the Lull
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Rupali S. Avasare, Jerry Yee (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Lupus Nephritis: How Far Have We Come, and Where Are We Headed?
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Iris J. Lee, Samir V. Parikh (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Lupus Nephritis and Kidney Transplantation: Where Are We Today?
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Tiffany Wong, Simin GoralLupus nephritis (LN) is the cause of end-stage kidney disease (ESKD) for 1.9% of the ESKD population in the United States. Although the incidence rates of ESKD from LN stopped rising in recent years, racial disparities in waiting time, pre-emptive kidney transplant, and transplant outcomes still exist. Patients with LN who progress to ESKD tend to be female, of African ancestry, and young. Kidney transplantation is safe in this population and associated with a substantial survival benefit, prima...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Classification of Lupus Nephritis; Time for a Change?
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Michael B. Stokes, Vivette D. D'AgatiRenal biopsy plays a critical role in the diagnosis and management of kidney disease in patients with systemic lupus erythematosus. The current pathologic classification of lupus nephritis is widely accepted but remains a work in progress. We discuss the key challenges in lupus nephritis classification and review new approaches to improve clinical utility and prognostic value. (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Pregnancy in Women With Systemic Lupus and Lupus Nephritis
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Sharon Maynard, Grace Guerrier, Margaret DuffyPregnancy is an altered immunologic state in which hormonal changes impact the immune system to enable maternal tolerance of the fetus. These hormonal and immunologic changes may affect disease activity in systemic lupus erythematosus. Conversely, lupus nephritis and its complications may adversely impact pregnancy. Systemic lupus erythematosus increases the risk of pre-eclampsia and its complications, including preterm birth and intrauterine growth restriction. Comorbiditie...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Moving Forward With Biologics in Lupus Nephritis
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Liliane Hobeika, Lauren Ng, Iris J. LeeThe majority of patients with systemic lupus erythematosus develop lupus nephritis (LN) which significantly contributes to increased risks of hospitalizations, ESRD, and death. Unfortunately, treatments for LN have not changed over the past 15 years. Despite continued efforts to elucidate the pathogenesis of LN, no new drugs have yet replaced the standard-of-care regimens of cyclophosphamide or mycophenolate mofetil plus high-dose corticosteroids. The significant limitations o...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Utilization of Biomarkers in Lupus Nephritis
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Dawn J. Caster, David W. PowellLupus nephritis (LN) occurs in up to 60% of SLE patients, and is a leading cause of disability and death. Current treatment of LN consists of a combination of high dose corticosteroids that non-specifically decrease inflammation and cytotoxic medications that reduce auto-antibody production. That combination of therapy is associated with significant side effects while remission rates remain inadequate. Since the introduction of biologics into the pharmacological armamentarium, there has be...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

The Kidney Biopsy in Systemic Lupus Erythematosus: A View of the Past and a Vision of the Future
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Isabelle Ayoub, Clarissa Cassol, Salem Almaani, Brad Rovin, Samir V. ParikhThe kidney biopsy advanced our understanding of kidney disease in systemic lupus erythematosus. It allowed for better recognition and classification of lupus nephritis (LN). Several LN classifications have been devised in an effort to inform treatment decision and predict prognosis, and these are being further updated. In this review, we will examine the role of diagnostic as well as repeat kidney biopsy in the management of LN, including the pot...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Lupus Podocytopathy: An Overview
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Nestor Oliva-Damaso, Juan Payan, Elena Oliva-Damaso, Teresa Pereda, Andrew S. BombackIn systemic lupus erythematosus, nephrotic-range proteinuria typically signals the presence of a proliferative lupus nephritis (class III/IV) and/or membranous lupus nephritis (class V, with or without concomitant class III or IV lesions). However, in rare instances, systemic lupus erythematosus patients with nephrotic syndrome have kidney biopsy findings of normal glomeruli or focal segmental glomerulosclerosis lesions, with or without...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Elizabeth S. Kotzen, Sanjeet Roy, Koyal JainAntiphospholipid syndrome (APS) and other causes of thrombotic microangiopathy (TMA) negatively impact the renal outcomes of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Here we review the diagnosis and management of occlusive renal vascular lesions due to APS and other TMAs, with a focus on patients with SLE and lupus nephritis. The presence of a thrombotic event, unexplained hypertension, thrombocytopenia, or hemolytic anemia should prompt considerat...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Lupus Nephritis: Duration of Therapy and Possibility of Withdrawal
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Latisha Heinlen, Eliza F. ChakravartyLupus nephritis is the most common organ-threatening manifestation of systemic lupus erythematosus, affecting more than one-third of patients. Induction of remission and maintenance of relapse-free disease have been and continue to be a critical focus of investigation. Because the need for renal replacement therapy in those with an insufficient response to therapy is associated with significantly increased morbidity and mortality, providers and patients are willing to accept moderate...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Membranous Lupus Nephritis: A Clinical Review
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Salem Almaani, Samir V. ParikhMembranous lupus nephritis (MLN) (Class V lupus nephritis [LN]) is a distinct form of LN defined by the presence of subepithelial immune complex deposits seen on kidney biopsy. MLN is often associated with the nephrotic syndrome. The histology of MLN closely resembles that of idiopathic (primary) membranous nephropathy (pMN). However, MLN typically has abundant mesangial deposits that are absent in primary membranous nephropathy. The clinical presentation, management, and prognosis of MLN d...
Source: Advances in Chronic Kidney Disease - November 14, 2019 Category: Urology & Nephrology Source Type: research

Masthead
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Editorial Board
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Table of Contents
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Erythropoiesis-Stimulating Agents and Cancer: Myth or Truth
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Michael J. Choi, Jerry Yee (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No Longer Business as Usual?
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Jay B. Wish (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Jonathan Bazeley, Jay B. WishSince the introduction of erythropoiesis-stimulating agents (ESAs) into clinical practice in 1989, considerable effort has been put forth toward identifying the optimal treatment strategy for managing anemia of CKD. After initial treatment of only the most severely anemic patients, therapy was subsequently expanded to include most patients on dialysis and many nondialysis CKD patients. Many nephrology societies and regulatory agencies have sought to identify the most appropriate hemoglobin levels...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Low Quality of International Classification of Diseases, 10th Revision, Procedural Coding System Data Undermines the Validity of the Standardized Transfusion Ratio: Time to Chart a New Course?
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Eric D. Weinhandl, Kristine M. Kubisiak, James B. WetmoreThe validity of the standardized transfusion ratio, a quality measure for dialysis facilities, may have been affected by the transition from International Classification of Diseases, Ninth Revision (ICD-9) to International Classification of Diseases, Tenth Revision (ICD-10) procedure coding in October 2015. We analyzed Medicare Part A claims for inpatient care among dialysis patients in 2014-2017 and investigated billing patterns for blood transfusion during the last y...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

The Impact of Anemia Treatment on Health-Related Quality of Life in Patients With Chronic Kidney Disease in the Contemporary Era
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Fredric O. Finkelstein, Susan H. FinkelsteinThe treatment of anemia with erythropoietic-stimulating agents is now part of the routine care of patients with CKD with guidelines for anemia management carefully outlined by Kidney Disease Improving Global Outcomes. The treatment of anemia impacts the health-related quality of life of CKD patients, primarily affecting the domains of energy/vitality and physical functioning. Improvements in these domains occur, in general, most noticeably when hemoglobin levels are raised from bel...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Neil S. Sanghani, Volker H. HaaseProlyl hydroxylase domain oxygen sensors are dioxygenases that regulate the activity of hypoxia-inducible factor (HIF), which controls renal and hepatic erythropoietin production and coordinates erythropoiesis with iron metabolism. Small molecule inhibitors of prolyl hydroxylase domain dioxygenases (HIF-PHI [prolyl hydroxylase inhibitor]) stimulate the production of endogenous erythropoietin and improve iron metabolism resulting in efficacious anemia management in patients with CKD. Three ora...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Hitesh H. Shah, Steven FishbaneAnemia is a well-known complication of advanced CKD and treatment with erythropoietin analogues (epoetin) remains a key component of management. Although biologic agents, including epoetin, play an extremely important role in the treatment of various medical conditions, their cost can be prohibitive. As a result, several biosimilar agents have now been approved by the U.S. Food and Drug Administration. Biosimilar epoetin has been used in Europe since 2007. In this article, we will review biosim...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease
This article covers current treatment guidelines for patients with anemia and CKD and clinical trial data for iron-repletion agents currently in use, as well as for novel oral iron therapies in development. Ferric citrate, a novel oral iron-repletion agent approved for patients with non-dialysis-dependent CKD and IDA, demonstrated improvements in hemoglobin levels and iron parameters, with good tolerability in patients with non-dialysis-dependent CKD. When used as a phosphate binder, ferric citrate also improves hemoglobin and iron parameters in dialysis-dependent CKD, but additional trials are needed to evaluate its effic...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Abhijit V. Kshirsagar, Xiaojuan LiPatients with end-stage renal disease on dialysis commonly receive intravenous iron to treat anemia along with erythropoiesis-stimulating agents. While studies of intravenous iron have demonstrated efficacy in raising hemoglobin, the quantity of administered intravenous iron has raised concerns about iron overload leading to long-term toxicities. The goal of this review is to understand recent trends in intravenous iron use, potential mechanisms of iron toxicity, and to evaluate the availabl...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Hepcidin
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Anil K. Agarwal, Jerry YeeDysregulation of metabolism and utilization of iron can lead to the development and maintenance of anemia of CKD. Anemia is prevalent among patients with CKD. The markers of iron sufficiency or availability of iron are far from perfect which results in inaccurate diagnosis and treatment of anemia with poor outcomes. Hepcidin, a 25 amino acid peptide produced by the hepatocytes, has emerged as the key regulator of uptake and release of iron in the tissues to maintain a steady supply of iron to erythr...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research

Masthead
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Editorial Board
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Table of Contents
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Eradicating the Viral Triad in Hemodialysis Units
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Beth Adams, Jerry Yee (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Warning: Kidney Virus Detected
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): James E. Novak (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Common Mechanisms of Viral Injury to the Kidney
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Leslie A. BruggemanViral infections in an immunocompetent host can cause both acute and chronic kidney diseases, either by direct damage to the infected kidney cells or as a consequence of systemic immune responses that impact the kidneys' function. Viruses have evolved mechanisms to hijack signaling pathways of the infected cell, including the mammalian target of rapamycin pathway to support viral replication, and to evade antiviral immune responses such as those mediated by miR-155 via microRNA mimetics expressed by the vir...
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Emerging Threat: Changing Epidemiology of Hepatitis A and Acute Kidney Injury
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Maria Andrievskaya, Adrienne Lenhart, Junior UdumanIn the past decade, hepatitis A has been considered a rare disease in the United States, largely due to targeted vaccination of at-risk children. Evolving epidemiology has resulted in decreasing immunity and increasing hepatitis A infections among adults who are more likely to experience severe disease. A surge in outbreaks has been noted in the past 2 years, resulting in a high volume of hepatitis A related hospitalizations and complications in otherwise healthy individ...
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

Preventing Hepatitis B in the Dialysis Unit
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Vivek Soi, Sandeep SomanPatients with end-stage renal disease are at risk for contracting hepatitis B virus (HBV) because of their exposure to blood products and compromised immune status. Despite a decrease in the incidence of HBV infection, continued vigilance in the form of surveillance is imperative in preventing the spread of this robust DNA virus. Regular review of serologic markers with isolation and decontamination practices as appropriate are paramount to maintaining a safe environment for dialysis to occur. Vaccinat...
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research

The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Krishna Sury, Mark A. PerazellaIn nearly 40 years since human immunodeficiency virus (HIV) first emerged, much has changed. Our understanding of the pathogenesis of HIV infection and its effect on the cells within each kidney compartment has progressed, and the natural history of the disease has been transformed. What was once an acutely fatal illness is now a chronic disease managed with oral medications. This change is largely due to the advent of antiretroviral drugs, which have dramatically altered the prognosis and ...
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research